



EXPRESS MAIL CERTIFICATE

Date _____ Label No. _____

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.



RECEIVED

DEC 05 2003

TECH CENTER 1600/2900

Name (Print) _____

Signature _____

PLEASE CHARGE ANY DEFICIENCY OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Customer No.: **07278**

File No.: 00342/100H395-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Vadim Bichko et al.

Serial No.: 10/005,469

Group Art Unit: 1648

Filed: November 7, 2001

Examiner: Bao Qun Li

Confirmation No.: 7244

For: HEPATITIS C VIRUS CONSTRUCTS CHARACTERIZED BY HIGH EFFICIENCY
REPLICATION

AMENDMENT AND RESPONSE TO THE OFFICE ACTION

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed on June 3, 2003, please consider the following amendments and remarks. Amendments to the claims are reflected in the listing of claims which

{M:\0342\1h395\00065425.DOC *03421H395* }

begins on page 3 of this paper. Remarks begin on page 7 of this paper. Submitted simultaneously herewith is (i) a Petition for THREE (3) MONTHS Extension of Time with the required fees, (ii) a Request to Correct Inventorship pursuant to 37 C.F.R. § 1.48 seeking to add Victor Shifrin and Svetlana Bergelson as co-inventors accompanied by Declaration of Victor Shifrin (Exhibit A), Declaration of Svetlana Bergelson (Exhibit B), Declaration of Vadim Bichko (Exhibit C), Written Consent of Assignee, Anadys Pharmaceuticals, Inc. (Exhibit D; *the attached document is not signed, a signed document will be provided shortly - as soon as received from the Assignee*), and Assignment from Victor Shifrin and Svetlana Bergelson to Anadys Pharmaceuticals, Inc. (Exhibit E) (all attached herein as Tab 1) with the required fees, and (iii) a Supplemental Information Disclosure Statement and Form PTO/SB/08A (attached as Tab 2).